Peak Bio, Inc. (PKBO) Research

Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.

Market snapshot

Symbol
PKBO
Price
$0.02
Market cap
$520.3K
P/E ratio
-1.91x
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Biocept, Inc. (BIOC)
  • Bellicum Pharmaceuticals, Inc. (BLCM)
  • Infinity Pharmaceuticals, Inc. (INFIQ)
  • Ontrak, Inc. (OTRK)
  • BiomX Inc. (PHGE)
  • Phio Pharmaceuticals Corp. (PHIO)
  • TC Biopharm (Holdings) Plc (TCBP)
  • TFF Pharmaceuticals, Inc. (TFFP)

Recent insider activity

  • SBI INVESTMENT KOREA CO., LTD. — J-Other (83800 shares) on 2024-10-07
  • SBI INVESTMENT KOREA CO., LTD. — D-Return (3621489 shares) on 2024-11-14
  • Patel Sandip I — C-Conversion (763316 shares) on 2024-11-14
  • Patel Sandip I — C-Conversion (0 shares) on 2024-11-14
  • Patel Sandip I — D-Return (47364 shares) on 2024-11-14

Open Peak Bio, Inc. (PKBO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.